Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Yang S, Zhang X, Gale RP, Du X, Chen CY, Weng JY, Huang J, Li F, Zeng Y, Xiao Z, Hu JD, Yang LJ, Liu ZG, Li GH, Sun XL, Yang W, Feng R, Han YQ, Jing Y, Xu N, Liu XL, Liu ZF, Wang XD, Wu SX, Liang R, Zhang YL, Yang YF, Zhu HL, Pan L, Meng L, Zhao YH, Yi H, Liu YL, Zhang WH, Zheng YJ, Zhou ZP, Chen SN, Qiu HY, Li WM, Jia ZL, Bai YL, Lin LE, Liu BC, Liu CS, Luo JM, Meng JX, Sun ZQ, Zhang YQ, Huang XJ, Jiang Q. Yang S, et al. Among authors: zhou zp. Am J Hematol. 2023 Jul;98(7):E183-E186. doi: 10.1002/ajh.26943. Epub 2023 May 2. Am J Hematol. 2023. PMID: 37128776 No abstract available.
[Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients].
Sun AN, Tian XP, Cao XS, Ouyang J, Gu J, Xu KL, Yu K, Zeng QS, Sun ZM, Chen GA, Gao SJ, Zhou J, Wang JH, Yang LH, Luo JM, Zhang M, Guo XH, Wang XM, Zhang X, Shi KQ, Sun H, Ding XM, Hu JD, Zheng RJ, Zhao HG, Hou M, Wang X, Chen FP, Zhu Y, Liu H, Huang DP, Liao AJ, Ma LM, Su LP, Liu L, Zhou ZP, Huang XB, Sun XM, Wu DP. Sun AN, et al. Among authors: zhou zp, zhou j. Zhonghua Xue Ye Xue Za Zhi. 2017 Dec 14;38(12):1017-1023. doi: 10.3760/cma.j.issn.0253-2727.2017.12.003. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29365393 Free PMC article. Chinese.
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age.
Zhao P, Hou M, Liu Y, Liu HX, Huang RB, Yao HX, Niu T, Peng J, Jiang M, Han YQ, Hu JD, Zhou H, Zhou ZP, Qiu L, Zhang LS, Wang X, Wang HQ, Feng R, Yang LH, Ma LM, Wang SQ, Kong PY, Wang WS, Sun HP, Sun J, Zhou HB, Zhu TN, Wang LR, Zhang JY, Huang QS, Liu X, Fu HX, Li YY, Wang QF, Jiang Q, Jiang H, Lu J, Zhang XH. Zhao P, et al. Among authors: zhou h, zhou zp, zhou hb. Platelets. 2021 Jul 4;32(5):633-641. doi: 10.1080/09537104.2020.1786042. Epub 2020 Jul 2. Platelets. 2021. PMID: 32614630
A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data.
Wu YJ, Hou M, Liu HX, Peng J, Ma LM, Yang LH, Feng R, Liu H, Liu Y, Feng J, Zhang HY, Zhou ZP, Wang WS, Shen XL, Zhao P, Fu HX, Zeng QZ, Wang XL, Huang QS, He Y, Jiang Q, Jiang H, Lu J, Zhao XY, Zhao XS, Chang YJ, Xu LP, Li YY, Wang QF, Zhang XH. Wu YJ, et al. Among authors: zhou zp. Blood Adv. 2020 Nov 24;4(22):5846-5857. doi: 10.1182/bloodadvances.2020003074. Blood Adv. 2020. PMID: 33232474 Free PMC article.
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.
Chong S, Zhao P, Huang RB, Zhou H, Zhang JN, Hou M, Liu Y, Yao HX, Niu T, Peng J, Jiang M, Han YQ, Hu JD, Zhou ZP, Qiu L, Zhang LS, Wang X, Wang HQ, Feng R, Yang LH, Ma LM, Wang SQ, Kong PY, Wang WS, Sun HP, Sun J, Zhou HB, Zhu TN, Wang LR, Zhang JY, Huang QS, Fu HX, Wu YJ, Li YY, Wang QF, Jiang Q, Jiang H, Lu J, Huang XJ, Zhang XH. Chong S, et al. Among authors: zhou h, zhou zp, zhou hb. Blood Adv. 2022 Jul 26;6(14):4320-4329. doi: 10.1182/bloodadvances.2022007226. Blood Adv. 2022. PMID: 35679462 Free PMC article.
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yu W, Jin J. Zhang Y, et al. Am J Hematol. 2022 Dec;97(12):1510-1519. doi: 10.1002/ajh.26709. Epub 2022 Oct 4. Am J Hematol. 2022. PMID: 36054786 Free PMC article. Clinical Trial.
Validation of the imatinib-therapy failure model.
Zhang X, Gale RP, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, Chen C, Lin H, Li G, Liang R, Liu Z, Wang X, Zhang Y, Han Y, Liu C, Hu J, Lin L, Yang W, Liu Z, Meng L, Tu C, Zheng C, Zhou Z, Bai Y, Qiu H, Chen S, Li F, Guo J, Liu Z, Sun H, Zhou L, Feng R, Sun X, Huang X, Jiang Q. Zhang X, et al. Leukemia. 2023 May;37(5):1166-1169. doi: 10.1038/s41375-023-01875-3. Epub 2023 Mar 27. Leukemia. 2023. PMID: 36973351 No abstract available.
A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study.
An ZY, Wu YJ, Hou Y, Mei H, Nong WX, Li WQ, Zhou H, Feng R, Shen JP, Peng J, Zhou H, Liu Y, Song YP, Yang LH, Fang MY, Li JY, Cheng YF, Liu P, Xu YJ, Wang Z, Luo Y, Cai Z, Liu H, Wang JW, Li J, Zhang X, Sun ZM, Zhu XY, Wang X, Fu R, Huang L, Wang SY, Yang TH, Su LP, Ma LM, Chen XQ, Liu DH, Yao HX, Feng J, Zhang HY, Jiang M, Zhou ZP, Wang WS, Shen XL, Baima Y, Li YY, Wang QF, Huang QS, Fu HX, Zhu XL, He Y, Jiang Q, Jiang H, Lu J, Zhao XY, Chang YJ, Wu T, Pan YZ, Qiu L, Gao D, Jin AR, Li W, Gao SJ, Zhang L, Hou M, Huang XJ, Zhang XH; National Cooperative ITP Working Group. An ZY, et al. Among authors: zhou zp. Sci Bull (Beijing). 2023 Sep 30;68(18):2106-2114. doi: 10.1016/j.scib.2023.08.001. Epub 2023 Aug 3. Sci Bull (Beijing). 2023. PMID: 37599175 Free article.
Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China.
Zhou H, Zhou J, Wu D, Ma L, Du X, Niu T, Yang R, Liu J, Zhang F, Shi Q, Wang X, Jing H, Li J, Wang X, Cui Z, Zhou Z, Hou M, Shao Z, Jin J, Li W, Ren H, Hu J, Shen J, Liu L, Zeng Y, Zhou J, Liu X, Shen Y, Ding K, Taira T, Cai H, Zhao Y. Zhou H, et al. Res Pract Thromb Haemost. 2023 May 23;7(5):100192. doi: 10.1016/j.rpth.2023.100192. eCollection 2023 Jul. Res Pract Thromb Haemost. 2023. PMID: 37601010 Free PMC article.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yin H, Suo S, Yu W, Jin J. Zhang Y, et al. Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343062 Clinical Trial.
153 results